Stocks › PGNY
Progyny Inc (PGNY) stock analysis
WEAK BUY 13% confidence · analysed Sep 8, 2026
This analysis is from Sep 8, 2026 and may be out of date.
On Sep 8, 2026, our model rated Progyny Inc (PGNY) WEAK BUY with 13% confidence at a price of $26.00. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 56, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (1.0x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $28.75 and the swing low is $16.10; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The company reports a profit margin of 6.0% and revenue growth of +5.3%.
In its latest quarter it earned $0.55 per share, which beat the $0.53 analysts expected, with revenue +5.3% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $34.25.
The next earnings report is expected around Nov 5, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $26.20, a target of $27.07 (+3.3%) and a stop-loss at $24.81 (-5.3%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Sep 18, 2026 whatever the price does.
Research notes
PGNY’s bull case is still supported by a Moderate Buy consensus and average price targets around $33.91 to $40, implying meaningful upside from the current $25.94 price. The bear case is that the stock has been soft lately, trading around $25.66–$26.61 and roughly 1%–3% below recent levels, while some commentary says it is only near fair value on valuation metrics. The main recent catalyst is Progyny’s announced Sept. 8, 2026 presentation at the Wells Fargo Healthcare Conference, plus recent analyst reiterations such as Citizens’ $31 target and BTIG’s higher target mention. Overall, the latest public information and price action still agree with the prior positive view, though the market is not yet confirming a strong breakout.
The model's one-paragraph read
Leans BUY — composite score +0.13 (WEAK BUY). Technicals: RSI 55.9, MACD bullish, price below SMA50. Fundamentals: margin 6.0%, revenue growth 5.3%. Financial results: YoY revenue +5.3%, last EPS surprise +3.8%, next earnings 2026-11-05. Smart Money Concepts: ranging / no clear structure, price retesting a bearish order block. FinGPT news read: positive. Memory: 1 prior look(s); 0% of directional calls matched later price. Internet research: PGNY’s bull case is still supported by a **Moderate Buy** consensus and average price targets around **$33.91** to **$40**, implying meaningful upside from the current **$25.94** price. The bear case is that the stock has been soft lately, trading around **$25.66–$26.61** and roughly **1%–3% below** recent levels, while some commentary says it is only near fair value on valuation metrics. The main recent catalyst is Progyny’s announced **Sept. 8, 2026** presentation at the Wells Fargo Healthcare Conference, plus recent analyst reiterations such as Citizens’ **$31** target and BTIG’s higher target mention. Overall, the latest public information and price action still **agree with the prior positive view**, though the market is not yet confirming a strong breakout. Suggested levels: entry $26.2, target $27.07, stop-loss $24.81, exit by 2026-09-18 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for PGNY
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 8, 2026 | WEAK BUY | 13% | $26.00 | — | |
| Sep 2, 2026 | WEAK BUY | 13% | $26.52 | -2.0% | ✘ wrong direction |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
PHR · PRGO · SDZNY · SNN · STE · TCMD · TKNO · UNH · ZBH · ALC · AMGN · AMRX
Frequently asked questions
Is PGNY a buy right now?
As of Sep 8, 2026, our automated model rates Progyny Inc (PGNY) WEAK BUY with 13% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for PGNY?
The model's most recent plan targets $27.07 with a stop-loss at $24.81, from an entry near $26.20.
When does Progyny Inc report earnings next?
The next earnings report is expected around Nov 5, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.